Related Experiment Video

Updated: Jul 3, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Evidence for benefits of angiotensin receptor blockade beyond blood pressure control

Helmy M Siragy1

  • 1Department of Medicine, University of Virginia Health Center, PO Box 801409, Charlottesville, VA 22908, USA. hms7a@virginia.edu

Current Hypertension Reports
|July 16, 2008
PubMed

Insights

Blockading the renin-angiotensin system, particularly angiotensin II, offers significant cardiovascular and renal protection. This intervention helps prevent conditions like heart failure, myocardial infarction, and reduces diabetes risk.

Area of Science:

  • Cardiovascular Science
  • Endocrinology
  • Nephrology

Background:

  • Elevated angiotensin II levels contribute to oxidative stress and endothelial dysfunction, key factors in cardiovascular disease.
  • Angiotensin II exerts harmful effects mainly via the type 1 receptor, while the type 2 receptor may offer protection.
  • Angiotensin II receptor blockers (ARBs) inhibit these effects at the receptor level.

Purpose of the Study:

  • To summarize the vascular and cardioprotective benefits of blocking angiotensin II production or activity.
  • To highlight the renal protective effects of renin-angiotensin system blockade.
  • To discuss the impact on new-onset diabetes risk.

Main Methods:

  • Review of accumulating data on renin-angiotensin system blockade.
  • Analysis of studies investigating angiotensin II receptor blockers (ARBs).
  • Examination of effects on cardiovascular events and renal function.

Main Results:

  • Blockade of angiotensin II production or activity demonstrates significant vascular and cardioprotective benefits.
  • Reduced incidence of atrial fibrillation, acute myocardial infarction, and heart failure events observed.
  • Renal protection shown in diabetic and non-diabetic individuals, with a reduced risk of new-onset diabetes.

Conclusions:

  • Blocking the renin-angiotensin system provides substantial cardiovascular and renal protection.
  • Targeting angiotensin II pathways, especially via ARBs, is crucial for managing cardiovascular diseases.
  • This blockade strategy is beneficial for kidney health and diabetes prevention.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...